Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Decline in Short Interest

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 10,100 shares, a decline of 79.5% from the October 15th total of 49,200 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 28,000 shares, the short-interest ratio is currently 0.4 days.

Avalo Therapeutics Stock Performance

AVTX stock opened at $12.81 on Wednesday. The business has a fifty day simple moving average of $10.43 and a 200-day simple moving average of $11.15. Avalo Therapeutics has a 52 week low of $3.95 and a 52 week high of $34.46.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright started coverage on Avalo Therapeutics in a report on Thursday, October 24th. They issued a “neutral” rating for the company.

Institutional Trading of Avalo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Logos Global Management LP purchased a new stake in Avalo Therapeutics during the 2nd quarter worth $6,722,000. Ikarian Capital LLC purchased a new stake in Avalo Therapeutics during the 1st quarter worth $1,015,000. Finally, Affinity Asset Advisors LLC boosted its position in Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after purchasing an additional 35,000 shares during the period. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.